TP53 and central nervous system cancer: Regardless of p53 status in the glioma cells, celecoxib (8 and 30 μM, 72 hours treatment) did not cause any significant change in apoptosis population of U87MG, U87MG-PFT, U87MG-E6 and U373MG cells (P > 0.05, Figure 5).